Dermavant Sciences, a dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has announced positive results from the Phase III PSOARING 1 and PSOARING 2 studies. 27 August 2020
Massachusetts, USA-based DUSA Pharmaceuticals, a subsidiary of India’s Sun Pharmaceutical Industries, has agreed a settlement with the US Department of Justice (DoJ). 25 August 2020
Shares of US biotech Regeneron Pharmaceuticals were up 3% before the bell, but after the company posted what were better than expected second-quarter 2020 financial results, the stock dipped 1.36% to $639.63. 5 August 2020
The US Food and Drug Administration has approved an expanded indication for Stelara (ustekinumab) as a treatment for pediatric patients (six-11 years of age) who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis (PsO). 31 July 2020
AbbVie’s aspiring blockbuster Rinvoq (upadacitinib) is on course for a second indication following the presentation of pivotal Phase III results in atopic dermatitis (AD). 28 July 2020
UCB today announced positive results from the Phase IIIb BE RADIANT study, a direct comparison of the investigational interleukin (IL)-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Novartis’ (NOVN: VX) Cosentyx (secukinumab) in the treatment of adult patients with moderate-to-severe plaque psoriasis. 24 July 2020
LEO Pharma’s UK and Ireland business has appointed a new medical affairs lead, Amit Aggarwal, formerly director of UK medical affairs at Bayer. 23 July 2020
Privately-held Danish company MC2 Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Wynzora Cream (calcipotriene and betamethasone dipropionate) for once-daily topical treatment of plaque psoriasis in adults. 22 July 2020
Oral Janus kinase (JAK) inhibitor Rinvoq (upadacitinib) 15mg and 30mg, once daily monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase III study in individuals with moderate to severe atopic dermatitis. 22 July 2020
Privately held Danish drugmakers Union Therapeutics and LEO Pharma have completed a transaction for the former to acquire the global rights to the LEO PDE4 inhibitor compound series to be re-named UNI500. 21 July 2020
Swiss pharma giant Novartis was trading 1.5% lower on Tuesday lunchtime after presenting its financial results for the second quarter of 2020. 21 July 2020
Eli Lilly today announced that its mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of interleukin (IL)23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. 17 July 2020
Johnson & Johnson’s Janssen unit has announced that the US Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA). 14 July 2020
Amid the ever-tightening competition in the Russian pharmaceutical market, global drugmakers continue to cut their local range as part of efforts for optimization of local business, reports The Pharma Letter’s local correspondent. 14 July 2020
Endo International has been granted US Food and Drug Administration approval for Qwo (collagenase clostridium histolyticum-aaes), a treatment for cellulite. 7 July 2020
The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024